B. Han

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial

Changgui Li, Q. Gao, Zhiwei Jiang, 2021, The Lancet Infectious Diseases.

Six-month follow-up of a booster dose of CoronaVac in two single-centre phase 2 clinical trials

Xinhua Chen, Qianhui Wu, K. Chu, 2022, Nature Communications.

Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials

Wen Zheng, Qianhui Wu, Juan Yang, 2021, The Lancet Infectious Diseases.

A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

J. Yang, X. Deng, W. Zheng, 2021, medRxiv.

Immune persistence 17 to 20 years after primary vaccination with recombination hepatitis B vaccine (CHO) and the effect of booster dose vaccination

Feng Wang, Yu-liang Zhao, Tian-Li Ma, 2019, BMC Infectious Diseases.

Immune response to different types of hepatitis B vaccine booster doses 2 to 32 years after the primary immunization schedule and its influencing factors.

Yan-hong Zhang, Feng Wang, Yu-liang Zhao, 2020, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Safety, Tolerability and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Healthy Children and Adolescents: A Randomised, Double-Blind, and Placebo-Controlled, Phase 1/2 Clinical Trial

Changgui Li, Lei Wang, Q. Gao, 2021, Social Science Research Network.